iCAD (ICAD) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
1 Feb, 2026Executive summary
Achieved 21% year-over-year revenue growth in Q2 2024, reaching $5.0 million, driven by expanded sales, upgrades, and a strategic shift to SaaS, cloud, and subscription offerings.
Gross profit margin improved to 84% in Q2 2024 from 81% in Q2 2023, reflecting higher software license revenue and operational efficiency.
Net loss from continuing operations narrowed to $1.7 million ($0.07/share) in Q2 2024 from $2.3 million ($0.09/share) in Q2 2023.
Annual Recurring Revenue (ARR) rose 7% to $9.2 million, reflecting momentum in subscription and cloud offerings.
Launched ProFound Cloud SaaS platform, with strong initial customer uptake and a more predictable revenue model.
Financial highlights
Q2 2024 revenue was $5.0 million, up 21% year-over-year; six-month revenue was $10.0 million, up 17% year-over-year.
Q2 2024 gross profit was $4.2 million (84% margin); six-month gross profit was $8.3 million (83% margin).
GAAP net loss for Q2 2024 was $1.7 million ($0.07/share), improved from $2.3 million ($0.09/share) in Q2 2023.
Non-GAAP adjusted EBITDA loss improved to $1.2 million in Q2 2024, down from $2.1 million in the prior year.
Cash and equivalents at June 30, 2024, were $20.4 million; net cash used in operations improved 43% year-over-year.
Outlook and guidance
Management anticipates continued growth in cloud and SaaS adoption, with recurring revenue models providing greater predictability.
Expects to be active in new international markets within 12 months.
Liquidity is considered sufficient to sustain operations for at least the next 12 months.
Latest events from iCAD
- Cloud-based AI and strategic partnerships drive growth in mammography diagnostics.ICAD
17th Annual LD Micro Main Event Conference18 Jan 2026 - Q3 2024 revenue up 4% to $4.2M, ARR at $9.3M, and FDA clearance boosts future growth.ICAD
Q3 202414 Jan 2026 - Double-digit revenue and ARR growth driven by SaaS, cloud, and new AI product launch.ICAD
Q4 202426 Dec 2025 - $103M all-stock deal unites AI breast imaging leaders, boosting growth and global reach.ICAD
Status Update23 Dec 2025 - Q1 2025 saw stable revenue, improved margins, and a pending RadNet acquisition.ICAD
Q1 20256 Jun 2025